APR 0 7 2003 Complete if Known TA TRADENATE ite for form 1449A-B/PTO 09/747,287 **Application Number** Decemb r 22, 2000 INFORMATION DISCLOSURE Filing Date **Beverly Packard** STATEMENT BY APPLICANT First Named Inventor 1645 **Group Art Unit** Unassigned **Examiner Name** (use as many sheets as necessary) 60 300-948600US Attorney Docket Number **Date Submitted** April 2, 2003

					•	<u>~</u> `
			U.	S. PATENT DOCUMENTS		
Examiner Initials	Cite No.	U.S. Patent Do Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
CH K	1.	5,011,910		Marshall et al.	04-30-1991	
	2	5,110,801		Leveen et al.	05-05-1992	
	3	5,118,801		Lizardi et al.	06-02-1992	
	4	5,312,728		Lizardi et al.	05-17-1994	
	5	5,506,115		Toth et al.	04-09-1996	
	6	5,652,107		Lizardi et al.	07-29-1997	
	7	5,698,41,1		Lucas et al.	12-16-1997	
	8	5,714,342		Kornoriya et al.	02-03-1998	
CHK	9	5,759,773		Tyagi et al.	06-02-1998	
	10-	5,773,719	-	Jaffe et al.	-06-30-1998	
CIK	11	5,776,720		Jaffe et al.	07-07-1998	
CMK	12	5,807,674		Tyagi et al.	09-15-1998	
	-13-	5,871,846		Lucas et al.	02-16-1999	
CAK	14	5,925,517		Tyagi et al.	07-20-1999	
	15	6,037,103		Tyagi et al.	03-14-2000	
CYK	16	6,037,130		Tyagi et al.	03-14-2000	
CMK	17	6,103,476		Tyagi et al.	08-15-2000	
	18	6,130,476		Tyagi et al.	10-10-2000	
CMK	. 19	6,150,097		Tyagi et al.	11-21-2000	,

				FOREIGI	N PATENT DOCUMEN			
Examiner Initials	Cite No.	Office	Foreign Patent Docu Number	ment Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т
CYK	20	WO	00/06778	A1	The Public Health Research Institute of the City of New York, Inc.	02-10-2000		

Examiner Signature	· chi	Date Considered	10/22/04

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Complete if Known or form 1449A-B/PTO Application Number Filing Date 09/747,287 TRANSPORMATION DISCLOSURE December 22, 2000 Bev rly Packard First Named Inventor STATEMENT BY APPLICANT 1645 Group Art Unit Unassign d **Examiner Name** (use as many sheets as necessary) 300-948600US Attorney Docket Number **Date Submitted**

CMK	21	wo	00/71562	A1	The Public Health Research Institute of the City of New York, Inc.	11-30-2000	659/2009	2003
	22	wo	00/71740	A1.	The Public Health Research Institute of the City of New York, Inc.	11-30-2000		
	23	wo	01/31062	A1	The Public Health Research Institute of the City of New York, Inc.	05-03/2001		,
	24	wo	97/39008	A1	The Public Health Research Institute of the City of New York, Inc.	10-23-1997		
cM)	25	wo	98/10096		The Public Health Research Institute of the City of New York, Inc.	03-12-1998	7	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Çite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
CMK	on Ekert et al. EMBO J. 18(2):330-338 (1999)		
1	27	Finucane et al. Abstract J. Biol. Chem 274(4):2225-2233 (1999)	
	28	Harvey et al. Jol. Of Cell Biol. 148(1) (2000), pages 57-92	
	29	Hirata et al. J. of Exp Med. 187(4) (1998) , Pages 587-600.	
CMK	30	Kanuka et al. <i>PNAS USA</i> 96:145-150 (1999)	
	31	Komorlya Cambridge Health Inst. (2001)	<u> </u>
CIK	32	Komoriya et al. J. of Exp. Mel 191(11):1819-1829 (2000)	
	33	Packard et al. Abratacts 40th Annual Meeting (1996)	
CYK	34	Packard et al. Biochysical Chemistry 67 167-176 (1997) Biophysical	
CHK	35	Packard et al. J. Phys. Chem 101:5070-5074 (1997)	

Examiner	CBL	Date	10/22/04
Signature		Considered	<u> </u>

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	APR 0 7 200	3 .:}	(Modified) F pproved for use through 10/3			
Substitute fo	or form 1449A-B/PTO	C	omplete if Known	•		
Cubbindis	or form 1449A-B/PTO	Application Number	09/747,287			
INFORM/	ATION DISCLOSURE	Filing Date	December 22, 2000	7		
	ENT BY APPLICANT	First Named Inventor	Beverly Packard	₽	: -	
0		Group Art Unit	1645	7	A	רל
	·	Examiner Name	Unassign d	Ξ	ÞΕ	
(use as	many sheets as necessary)	Attorney Docket Number	300-948600US			
	•	Date Submitted		_;;;	9	_25
				16	<u>ب</u>	
CAK 36	Packard et al. J. Phys. Chem	752-758 (1998) 3	· · · · · · · · · · · · · · · · · · ·	200/2	2003	m
37	Packard et al. J. Phys. Chem.	1820-1827 (1998)		906		D
CHK 38	Packard et al. Methods in Enz	ymology 278:15-28 (1997)				
39	Packard et al. PNAS USA 93:	11640-11645 (1996) Dec	P of new	L		
07/c 40	Perez et al. Molecular Human					
CMK 41	Robles et al. Endocinology (19	999) ABSTRACT , Vol	140, NOG, PZ	541-26	,44	
42	Siegel et al. Jol. Of Call Ciel.	141(5) (1998)				
Cart 43	Zapata et al. Jol. Of Biol Chen	n. 273(12):6916-6920 (1998)			

		<u> </u>		
Examiner	(6)		Date	10/22/01
Signature			Considered	1709

: •	.·		OIPETO		
1	Substitu	de for form: 1449A-B/PTO	APR 1 7 2007 6	(Modified) PTO/SB/08A-Approved for use through 10/31/99, OMB 06	B (10-96) 351-0031
.1			L\2. #1 6	omplete if Known	
1	INFOR	MATION DISCLOSURE		09/747,287	
1	SIAI	MENT BY APPLICANT	Filing Dalianus	D cemb r 22, 2000	
1	•	•	First Named Inventor	Beverly Packard	
1	lus	9 Re manual	Group Art Unit	Unassign d	
1	,,,,,	e as many sheets as necessary)	Examiner Name	Unassigned	
 			Attorney Docket Number	300-040000110	
100	MC AS	LATT ET AL. "Flourescence D Electronic Energy Transfer." A	Date Submitted	April 0 2000	
-	1-1-	Electronic Energy Transfer. A MATAYOSHI ET AL. "Novel F	nabriant Dis	tidase A Activity Based as	
1 1	/ . A1	MATAYOSHI ET AL "Novel E	lugranal Blochemistry 50:56	(1972) Sasaying Retroviral Proteases by	1: 1
 		RHSDNanco Engan. T	A ANT SAIRIJOUG SITURE INF A	and a second	
1 • 1	AL	Resonance Energy Transfer.* MATSUZAKI ET AL. *Transloc.*	ation of a Other 1990) p 45	Antimicrobial Peptide, Maganin 2,	11
 	 - -				
1. 1	ΑV	across Lipid Bilayers by Formir NAGASE ET AL. "Design and (Hydrolyzed by Stromelysin 1) PACKARD ET AL. Internal 1	Characteristic Biochemistry 34:	6521-6526 (1995) maganin 2,	11
1.	· AW	PACKARD ET AL. Intramolecul	lar Excitorio Di	9991c Substrate Selectively J. of Biol. Chem 269:20952 (1994) pase Substrated: Modification of the	1.1
	- 	Backbone Moiety to Probe the PARKHURST ET AL "Donor-Ad Fluorescent Olinonycloside Parkhurst Company Control of the Parkhurst Control	H-Dimer Structure in Prote	ase Substrated: Modification of the	╪┪
	- AX	PARKHURST ET AL "Donor-A	Contor Distance Di America	In Chem Society 1-8 (1000)	11,
ľ.	.] •	PARKHURST ET AL "Donor-Au Fluorescent Oligonucleotide Bot 34(1):293-300	th as a Single Standard	ns in a Double-Labeled	17
-1	1	Fluorescent Oligonucleotide Bot 34(1):293-300 (1995)	do a citudia strang and in	Duplexes." Biochemistry	1 1
- 1	AY	PARKHURST ET AL. "Kinetic Si Employing a Double-Labeked Oil Complement and to Single St	tudies by Elupenes		$\Gamma \Gamma$
_].	.}	Employing a Double-Labeked Of Complement and to Single Stran	igonucientide: Lightidica	onance Energy Transfer	╂╾┤╶
	AZ	Complement and to Single Stran WANG ET AL. "Design and Synt	d DNA Biochemistry 24000	to the Oligonucleotide	
_1.	المد	Besonance Fr. Design and Synt	hesis of New Floures	-292 (1995) .	
T:	ВА				
<u> </u>	ا ۲۰۰	218:1-13 /1004)	I drister, Methods and Appl		1 1
CHK	BB	YANG ET AL TOTAL	and Appl	Protease Substrates Based on 1990). ications." <i>Analytical Biochemistry</i>	 .
	1 22	YANG ET AL. "Conformational Fi Nucleotides." Biochemistry 35:79:	exibality of Three-Way Dara		.]
٠, -		Nucleotides. Biochemistry 35:79	59-7967 (1996)	Junctions Containing Inpaired	- -
•	• • •				. 4

J. phys. chem. B 1820-1827 (1998)

Signature	001		
Colgnature	Children -	Date	T 17
*EXAMINER: Initial I	réference considered	Considered	14/04

AMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in ormance and not considered. Include copy of this form with next communication to applicant.